Clinical trials: Influenza, Human
Influenza
Study of the Safety and Immunogenicity of NasoVAX Extension
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
- Trial name
- NCT03760549
- Testing
- Subjects were administered NasoVAX high dose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
- Trial name
- NCT00192140
- Testing
- FluMist
- Where
- 11 sites in United States
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1.
- Trial name
- NCT02743676
- Volunteers
- 648 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged 18 years or older.
- Trial name
- NCT01857297
- Testing
- Enzira® vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
FLU-v is a vaccine that aims to protect against a wide range of flu viruses. The purpose of this study is to measure the immune responses induced by FLU-v vaccine.
- Trial name
- NCT02962908
- Testing
- FLU-v, adjuvanted FLU-v, Saline
- Where
- Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza, Human
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody…
- Trial name
- NCT06028347
- Testing
- sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years.
- Trial name
- NCT02212106
- Testing
- bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
- Where
- 11 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above
In this study, the safety and immunogenicity of the current formulation of aTIV will be compared to aTIV-modified formulations in which the dosage of the MF59 adjuvant will be doubled or tripled and/or the dosage of the 3…
- Trial name
- NCT02126761
- Testing
- Adjuvanted, trivalent subunit influenza vaccine, Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine, Antigen level modified adjuvanted, trivalent subunit influenza vaccine
- Where
- Germany
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Influenza
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly…
- Trial name
- NCT02369341
- Testing
- Fluarix Tetra
- Where
- 2 sites in Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60…
- Trial name
- NCT02269852
- Testing
- trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Flu, Common Cold
A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold
The trial is an investigator-initiated, double-blind, randomized, placebo-controlled phase III study. After the patient has receiving information about the study and after given written informed consent, the patient will be…
- Trial name
- NCT01459952
- Testing
- Rose hip Liquid
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hyben Vital ApS
Influenza A
Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
- Trial name
- NCT02342249
- Testing
- VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg
- Where
- 176 sites in United States, Belgium and 7 more
- Volunteers
- 292 people
- Sponsor
- Janssen Research & Development, LLC
Influenza A
A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.
- Trial name
- NCT04683406
- Testing
- ZSP1273 600 mg, Oseltamivir(oral)
- Where
- 76 sites in China
- Volunteers
- 750 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine…
- Trial name
- NCT02554409
- Testing
- Quadrivalent Intradermal Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
To provide Centers for Biologic Evaluation and Research (CBER) with sera collected from healthy children receiving the 2007-2008 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study.
- Trial name
- NCT00561002
- Testing
- 2007-2008 Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2 Infection, Influenza A
Project STARFISH - PRJ0002679
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- STARFISH (NCT05727202)
- Testing
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Where
- 17 sites in United States
- Volunteers
- 1,909 people
- Sponsor
- Thermo Fisher Scientific, Inc
Influenza, Human
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a…
- Trial name
- NCT05648357
- Testing
- Fluarix Tetra Vaccine
- Where
- 6 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.